anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

119,821-119,880 of 319,975

filter-aware
01
Slide 1
Kerrisdale Capital research note; long position disclosure.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
02
The text is heavily redacted/corrupted in the source image, but the structure is clearly a table of contents.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
03
The text discusses the clinical problem of persistent AF and the technical limitations of existing contact mapping systems like CARTO.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
04
The slide uses a 'before-after' framing (traditional vs. AcQMap) to establish the superiority of the AcQMap technology.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
05
This is a research note from Kerrisdale Capital regarding Acutus Medical. It argues that past performance issues were temporary and are now resolved.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
06
Kerrisdale Capital research note page 6.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
07
The slide uses a medical diagram to explain the normal electrical function of the heart before introducing the concept of arrhythmia.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
08
This is a text-heavy research note page providing clinical context for a medical device investment thesis.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
09
The slide uses a medical illustration to explain the mechanism of action for a surgical procedure.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
10
This is a text-heavy research note page detailing medical trial outcomes and procedural methodologies.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
11
The slide serves as a critical analysis of current medical standards, positioning Acutus as a solution to the identified clinical void.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
12
The slide serves as a technical primer to establish the baseline technology before contrasting it with Acutus's solution.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
13
This is a text-heavy research note page from Kerrisdale Capital, focusing on the technical flaws of current contact-based mapping technologies in cardiac ablation.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
14
The slide is a text-heavy research note from Kerrisdale Capital critiquing current medical technology.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
15
The slide highlights the technological superiority of AcQMap's non-contact charge-density mapping over traditional contact mapping methods.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
16
The slide uses a medical imaging sequence to demonstrate the technological superiority of the AcQMap system over Acutus's legacy mapping.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
17
The slide uses clinical trial results as evidence to support the investment thesis regarding the efficacy of the AcQMap technology.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
18
The slide discusses a specific clinical study led by Betts and Wong, contrasting its methodology and outcomes with the UNCOVER trial.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
19
The text describes a shift from legacy contact mapping to a new, data-driven taxonomy of AF conduction patterns enabled by AcQMap.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
20
The text highlights specific time-saving metrics (10-15 mins vs 3 mins) and workflow advantages (multiple remappings).Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
21
This is a text-heavy research note slide summarizing qualitative feedback from Electrophysiologists (EPs).Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
22
Includes valuation metrics (EV/Revenue) and market opportunity sizing based on procedure volume and addressable market share.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
23
This is a standard text-heavy page from a research report rather than a presentation slide.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
24
The slide uses a narrative structure to explain a past financial performance dip while projecting future market growth for Acutus Medical.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
25
This is a text-heavy research note page detailing the 'stumbles' of Acutus Medical and the subsequent resolution of these issues.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
26
This is a standard text-heavy research report page rather than a traditional presentation slide.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
27
This is a text-heavy research note slide summarizing the investment case.Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
28
Acutus Medical Inc. (AFIB)Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
29
Acutus Medical Inc. (AFIB)Acutus Medical Inc. (AFIB) · Kerrisdale Capital
Research note Short seller 1 hit
18
The slide presents specific clinical data points (sample sizes, hit rates, false positives) to undermine the clinical validity of the AlloSure test.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
19
The slide uses data to challenge the clinical utility and market size of the AlloSure test.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
20
The slide uses a narrative structure to undermine the company's growth story by framing it as a 'house of cards'.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Beat · Thesis HeadlineLoop · Cost Of Inaction1 hit
21
The slide argues that CareDx effectively monetized the research process itself, creating a conflict of interest and a circular revenue model.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Beat · Thesis HeadlineLoop · Cost Of Inaction1 hit
22
The slide uses a footnote to perform a 'gap analysis' between management's cumulative patient claims and the quarterly growth figures.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
23
This is a research note page from Kerrisdale Capital, focusing on competitive analysis and product obsolescence.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
24
The slide discusses the impact of PAMA rules on Medicare reimbursement and the potential for price competition between Natera and CareDx.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
25
This is a research note from Kerrisdale Capital criticizing CareDx's market sizing methodology.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
26
This is a text-heavy research note page from a Kerrisdale Capital report.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
27
The slide uses a 'Valuing CareDx like Natera' comparison to justify a -70% downside estimate.CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller 1 hit
28
CareDx, Inc. (CDNA)CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller 1 hit
29
CareDx, Inc. (CDNA)CareDx, Inc. (CDNA) · Kerrisdale Capital
Research note Short seller 1 hit
01
Slide 1
The slide functions as a classic short-seller research note introduction, establishing the thesis and the firm's position.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Problem & Complication1 hit
02
Digital World Acquisition Corp (DWAC)Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Problem & Complication1 hit
03
This is a short-seller research note summary highlighting red flags.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Problem & Complication1 hit
04
This is a research note from Kerrisdale Capital regarding a short thesis on DWAC.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Problem & Complication1 hit
05
Includes a quote from a former SEC official to bolster the bearish thesis.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Problem & Complication1 hit
06
This is a research note from Kerrisdale Capital focusing on regulatory risks and SPAC merger delays.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller 1 hit
07
This is a research note from Kerrisdale Capital criticizing DWAC/TMTG.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Villain Critique1 hit
08
This slide is part of a short-selling research note by Kerrisdale Capital, focusing on the lack of business fundamentals in TMTG.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Villain Critique1 hit
09
The slide uses a 'villain_critique' approach to undermine the credibility of the company's management team disclosure.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Villain Critique1 hit
10
The slide uses a narrative approach to link past regulatory actions against ARC Global to the current DWAC situation.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
11
The slide uses a narrative approach to expose potential conflicts of interest and regulatory red flags.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Loop · Cost Of Inaction1 hit
12
This is a text-heavy research note slide focusing on investigative findings regarding corporate relationships.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Expose ContradictionLoop · Cost Of Inaction1 hit
13
Includes a direct excerpt from a court filing (Case No. 1:21-cv-02279-JPC) to support the claim of undisclosed conflicts.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Expose ContradictionLoop · Cost Of Inaction1 hit
14
The slide uses a narrative structure to build a case of regulatory misrepresentation by highlighting the overlap between DWAC's IPO process and TMTG merger discussions.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Expose ContradictionLoop · Cost Of Inaction1 hit
15
This is a text-heavy research note slide detailing a timeline of events to suggest potential misconduct.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Expose Contradiction1 hit
16
This is a text-heavy research note slide from Kerrisdale Capital arguing against the legitimacy of the DWAC-TMTG merger.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Preempt Rebuttal1 hit
17
Kerrisdale Capital research note criticizing Truth Social's operational performance.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Preempt Rebuttal1 hit
18
The slide uses a line chart to show declining app store rankings as evidence of poor performance.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Preempt Rebuttal1 hit
19
This is a text-heavy research note page from Kerrisdale Capital.Digital World Acquisition Corp (DWAC) · Kerrisdale Capital
Research note Short seller Beat · Preempt Rebuttal1 hit